Why the study?
Does phosphoramidon reduce the pressor response to big endothelin and lower blood pressure in spontaneously hypertensive rats?
Does phosphoramidon reduce the pressor response to big endothelin and lower blood pressure in spontaneously hypertensive rats?
Phosphoramidon blocks the pressor activity of big endothelin and lowers blood pressure in spontaneously hypertensive rats, identifying endothelin-converting enzyme as a novel metalloprotease and potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Supports ECE inhibition for BP lowering in hypertensive models; leaves open translation to human therapy.
In porcine aortic endothelial cells, the 21-amino acid peptide endothelin-1 (ET-1) is formed from a 39-amino acid intermediate big endothelin (big ET) by a putative endothelin-converting enzyme (ECE) that cleaves the 39-mer at the Trp21-Val22 bond. Because big ET has less than 1% of the contractile activity of ET-1, inhibition of ECE should effectively block the biological effects of big ET. Big ET injected intravenously into anesthetized rats produces a sustained pressor response that presumably is due to conversion of big ET to ET-1 by ECE. We determined the type of protease activity responsible for this conversion by evaluating the effectiveness of protease inhibitors in blocking the pressor response to big ET in ganglion-blocked anesthetized rats. The serine protease inhibitor leupeptin, the cysteinyl protease inhibitor E-64, and the metalloprotease inhibitors captopril and kelatorphan were ineffective at blocking the pressor response to big ET. However, the metalloprotease inhibitors phosphoramidon and thiorphan both dose-dependently inhibited the pressor response to big ET, although phosphoramidon was substantially more potent than thiorphan. None of the inhibitors blocked the pressor response to ET-1 and none had any effect on blood pressure when administered alone as an i.v. bolus to the ganglion-blocked anesthetized rat. However, phosphoramidon infused intravenously at 20 mg/kg/h for 4 h lowered the mean arterial pressure (MAP) in conscious spontaneously hypertensive rats (SHRs) whereas kelatorphan at the same dose did not. Our results suggest that ECE is a novel metalloprotease and that ECE inhibitors could have therapeutic potential for the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
McMahon et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: